斥资14.61亿元，同仁堂集团入主嘉事堂

Core Viewpoint - The acquisition of Jiasitang by Tongrentang Group marks a strategic move to enhance its pharmaceutical commercial segment and leverage Jiasitang's hospital channel resources to expand product sales and market share [1][2] Group 1: Acquisition Details - Jiasitang announced that its shareholders, Everbright Health and Everbright Industry, signed a share transfer agreement with Tongrentang Group, transferring 41.18 million shares and 41.87 million shares respectively at a price of 17.59 yuan per share, totaling approximately 1.461 billion yuan [1] - After the transaction, Tongrentang Group will hold 83.06 million shares of Jiasitang, representing a 28.48% stake, making it the controlling shareholder, while Everbright Industry and Everbright Health will exit completely [1] - The actual controller of Jiasitang will change from China Everbright Group to Beijing State-owned Assets Supervision and Administration Commission [1] Group 2: Market Reaction - Following the news of the acquisition, Jiasitang's stock hit the daily limit on February 4, before slightly retreating, closing up about 3% at 16.87 yuan per share [1] Group 3: Company Performance - Jiasitang's performance has been declining, with net profit dropping from 297 million yuan in 2022 to 161 million yuan in 2024, reflecting year-on-year declines of 16.09%, 15.79%, and 35.75% respectively [2] - For the first three quarters of 2025, Jiasitang reported revenue of 14.459 billion yuan, a year-on-year decrease of 21.80%, and a net profit of 141 million yuan, down 38.81% year-on-year [2] - The company's gross margin has fallen to 6.28% [2] Group 4: Tongrentang Group Overview - Tongrentang Group's business focuses on the production and sales of traditional Chinese medicine, forming a comprehensive health industry chain supported by pharmaceutical manufacturing, health maintenance, medical care, retail, and international pharmaceutical operations [2] - Tongrentang Group currently has three listed companies, and if the acquisition of Jiasitang is successful, it will add a fourth listed entity [2] - The core asset of Tongrentang is its traditional Chinese medicine business, which includes well-known products like Angong Niuhuang Wan and Niuhuang Qingxin Wan, although its performance has also faced challenges, with total revenue dropping to 13.308 billion yuan in the first three quarters of the previous year, a year-on-year decline of 3.7% [2]